151 related articles for article (PubMed ID: 32712768)
1. Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
Nahvijou A; Safari H; Yousefi M; Rajabi M; Arab-Zozani M; Ameri H
Breast Cancer; 2021 Jan; 28(1):130-136. PubMed ID: 32712768
[TBL] [Abstract][Full Text] [Related]
2. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
3. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
4. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
5. Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
Nahvijou A; Safari H; Ameri H
Breast Cancer; 2021 Jul; 28(4):937-943. PubMed ID: 33666840
[TBL] [Abstract][Full Text] [Related]
6. Exploring the consistency of the SF-6Dv2 in a breast cancer population.
Ameri H; Safari H; Poder T
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1017-1024. PubMed ID: 33107340
[No Abstract] [Full Text] [Related]
7. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
8. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
9. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.
Yang Q; Jiang LL; Li YF; Huang D
Health Qual Life Outcomes; 2023 Nov; 21(1):122. PubMed ID: 37964348
[TBL] [Abstract][Full Text] [Related]
11. Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to SF-6Dv2 in Chinese patients with heart failure.
Cong J; Zhu Y; Du J; Lin L; He Y; Zhang Q; Chye TO; Lv X; Liu W; Wu X; Ma F; Zhao X; Li Y; Long L
Health Qual Life Outcomes; 2022 Jun; 20(1):98. PubMed ID: 35725609
[TBL] [Abstract][Full Text] [Related]
12. Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.
Yang Q; Huang D; Jiang L; Tang Y; Zeng D
Front Endocrinol (Lausanne); 2023; 14():1160882. PubMed ID: 37664851
[TBL] [Abstract][Full Text] [Related]
13. Improving the mapping of condition-specific health-related quality of life onto SF-6D score.
Yang Y; Wong MY; Lam CL; Wong CK
Qual Life Res; 2014 Oct; 23(8):2343-53. PubMed ID: 24682669
[TBL] [Abstract][Full Text] [Related]
14. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
15. Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.
Poder TG; Fauteux V; He J; Brazier JE
Value Health; 2019 Jul; 22(7):837-842. PubMed ID: 31277832
[TBL] [Abstract][Full Text] [Related]
16. Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
[TBL] [Abstract][Full Text] [Related]
17. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
18. Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.
Wong CK; Lam CL; Rowen D; McGhee SM; Ma KP; Law WL; Poon JT; Chan P; Kwong DL; Tsang J
Value Health; 2012 May; 15(3):495-503. PubMed ID: 22583460
[TBL] [Abstract][Full Text] [Related]
19. Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer.
Wong CK; Lam CL; Wan YF; Rowen D
Value Health; 2013; 16(2):373-84. PubMed ID: 23538190
[TBL] [Abstract][Full Text] [Related]
20. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.
Kalaitzakis E; Benito de Valle M; Rahman M; Lindkvist B; Björnsson E; Chapman R; Kontodimopoulos N
Qual Life Res; 2016 Apr; 25(4):947-57. PubMed ID: 26471264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]